Loading...
Apremilast in the treatment of psoriatic arthritis: a perspective review
Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis. Established therapeutic options have variable effectiveness across the different domains of psoriatic disease...
Saved in:
| Published in: | Ther Adv Musculoskelet Dis |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315225/ https://ncbi.nlm.nih.gov/pubmed/28255338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X16673786 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|